Skip to main content

Table 2 Adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

ToxicityAll gradesGrade 3 or higher
 Febrile neutropenia  6(5.8%)
 Edema in limbs29(27.9%)0(0.0%)
  1. PN peripheral sensory neuropathy